Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 ± 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Patients’ report on how endometriosis affects health, work, and daily life
Fourquet, J., Gao, X., Zavala, D., Orengo, J. C., Abac, S., Ruiz, A., Laboy, J., & Flores, I. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.09.017 · Cited by 252 · cited 1×
“This condition often causes chronic pelvic pain, dysmenorrhea, and infertility and may negatively affect the quality of life in severe cases.(2,3) Surgery is generally recommended for the diagnosis and treatment of endometriosis, but medical treatment is also essential for managing endometriosis-related pain and preve…”
BackgroundStrowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 1×
“laparoscopy.(28) In a 24-week noninferiority trial, the efficacy for endometriosis pain was equivalent to that of leuprolide acetate, with less hypoestrogenic effect and more favorable effects on BMD.”
BackgroundReduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1941-7 · Cited by 200
Sasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177 · cited 1×
“Dienogest provides some pharmacological benefits with its high selectivity for progesterone receptors and progestogenic effects on the endometrium while it exerts minimal androgenic, mineralocorticoid, and glucocorticoid activities.(7,9,10) Gonadotropinreleasing hormone agonists are also well-established, effective tr…”
BackgroundSeracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Savelli, L., & Venturoli, S. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.083 · Cited by 158
Dienogest in the treatment of endometriosis
Bizzarri, N., Remorgida, V., Leone Roberti Maggiore, U., Scala, C., Tafi, E., Ghirardi, V., Salvatore, S., Candiani, M., Venturini, P. L., & Ferrero, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.943734 · Cited by 63
High-dose pilot study with the novel progestogen dienogestin patients with endometriosis
Schindler, A. E., Christensen, B., Henkel, A., Oettel, M., & Moore, C. (2006) · Gynecological Endocrinology · doi:10.1080/09513590500431482 · Cited by 53
Cho, S., Jung, J. A., Lee, Y., Kim, H. Y., Seo, S. K., Choi, Y. S., Lee, J. S., & Lee, B. S. (2014) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12294 · Cited by 39
Self-citation
Cited by
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa009 · Cited by 166
Zakhari, A., Edwards, D., Ryu, M., Matelski, J. J., Bougie, O., & Murji, A. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2020.05.007 · Cited by 86
Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H. (2018) · Reproductive Sciences · doi:10.1177/1933719118779733 · Cited by 44
“3%).(43) Despite no data, it might be also due to progesterone resistance in those with recurrent endometriosis, which might cause higher failure rate in treatment as well as higher rate of uterine bleeding.”
BackgroundSelf-citation
Metadata
- Authors
- Lee, S. R., Yi, K. W., Song, J. Y., Seo, S. K., Lee, D.-Y., Cho, S., & Kim, S. H.
- Venue
- Reproductive Sciences
- Published
- 2018-03
- Volume
- 25
- Issue
- 3
- Pages
- 341-346
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W2768613407
- Cited by
- 39
- References
- 9
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. https://app.cochat.ai/papers/10.1177/1933719117725820
- The paper
- Lee, S. R., Yi, K. W., Song, J. Y., Seo, S. K., Lee, D.-Y., Cho, S., & Kim, S. H. (2018). Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. Reproductive Sciences. https://doi.org/10.1177/1933719117725820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.